An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Detectnet

Chemical Name64Cu-DOTATATE
Dosage FormInjection (intravenous; 148 MBq (4 mCi), 37 MBq (1 mCi) per 1 mL)
Drug ClassRadioactive diagnostic agents
SystemEndocrine
CompanyCurium US LLC
Approval Year2020

Indication

  • For detection of the specific type of tumors called somatostatin receptor positive neuro-endocrine tumors (NETs) in adults.
Last updated on 12/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Detectnet (copper Cu 64 dotatate injection) Prescribing Information. 2020Curium US LLC., Maryland Heights, MO
Document TitleYearSource
64Cu-DOTATATE PET/CT for imaging patients with known or suspected somatostatin receptor–positive neuroendocrine tumors: results of the first U.S. prospective, reader-masked clinical trial. 2020The Journal of Nuclear Medicine
Head-to-head comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: a prospective study of 59 patients with neuroendocrine tumors. 2016The Journal of Nuclear Medicine
64Cu-DOTATATE PET for neuroendocrine tumors: a prospective head-to-head comparison with 111In-DTPA-octreotide in 112 patients. 2015The Journal of Nuclear Medicine